A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Phase of Trial: Phase III
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Paclitaxel (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors SynCore Biotechnology
- 06 Jul 2018 Status changed from not yet recruiting to recruiting.
- 26 Mar 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.
- 21 Mar 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.